Denali Therapeutics (DNLI)

P/S ratio as of November 2026 (TTM): 836

According to Denali Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.61. At the end of 2026 the company had a P/S ratio of > 1000.

P/S ratio history for Denali Therapeutics from 2017 to 2026

PS ratio at the end of each year

Year	P/S ratio	Change
2026	> 1000
2025	N/A
2024	N/A	-100%
2023	8.97	-74.23%
2022	34.8	-68.89%
2021	112	274.06%
2020	29.9	-52.36%
2019	62.8	314.81%
2018	15.1
2017	N/A

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Organovo ONVO	25.5	-96.95%	🇺🇸 USA
Orchard Therapeutics ORTX	17.4	-97.92%	🇬🇧 UK
Novavax NVAX	3.80	-99.55%	🇺🇸 USA
Novocure NVCR	2.21	-99.74%	Jersey

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Denali Therapeutics (DNLI)

P/S ratio as of November 2026 (TTM): 836